TEST BANK FOR LEHNE’S PHARMACOTHERAPEUTICS
FOR ADVANCED PRACTICE NURSES AND PHYSICIAN
ASSISTANTS 3RD EDITION ROSENTHAL |2026 UPDATE
SECTION 1: BASIC PRINCIPLES OF PHARMACOLOGY
(Questions 1-50)
QUESTION 1
A nurse administers the same medication in the same preparation in the same dose to
several patients and notes that some patients have a better response to the drug than
others. What is the most likely explanation for this phenomenon?
A) Altered bioavailability of the drug
B) Patient compliance with the therapeutic regimen
C) Pharmacogenomic differences among individuals
D) Placebo effects enhancing expectations of drug efficacy
Rationale: Pharmacogenomics is the study of how genetic variations affect individual
responses to drugs. Genetic polymorphisms can affect drug-metabolizing enzymes (e.g.,
CYP450), drug transporters, and receptor targets, leading to significant interindividual
differences in drug efficacy and toxicity .
,QUESTION 2
A patient asks a nurse why a friend who is taking the same drug responds differently to
that drug. The nurse knows that the most common variation in drug response is due to
differences in each patient's:
A) Drug receptor sites
B) Hypersensitivity potential
C) Metabolism of drugs
D) Psychosocial response
Rationale: Genetic variations in drug-metabolizing enzymes (e.g., CYP2D6, CYP2C9,
CYP3A4) are the most common cause of interindividual variation in drug response. These
variations affect the rate at which drugs are metabolized and eliminated, leading to
differences in drug levels and clinical effects .
QUESTION 3
The U.S. Food and Drug Administration (FDA) recommends genetic testing of patients
receiving certain medications. Genetic testing helps prescribers:
A) Better establish a drug's therapeutic index
B) Determine whether a patient is a rapid or slow metabolizer of the drug
C) Identify racial characteristics that affect psychosocial variation in drug response
D) Produce a drug that is tailored to an individual patient's genetic makeup
Rationale: Genetic testing identifies polymorphisms in drug-metabolizing enzymes (e.g.,
CYP2C9, CYP2D6, TPMT) that predict whether a patient is a poor, intermediate, or
extensive metabolizer. This information guides dosing decisions to optimize efficacy and
minimize toxicity .
QUESTION 4
What term does the nurse use to describe the drug level required to have a therapeutic
effect?
,A) Critical concentration
B) Dynamic equilibrium
C) Selective toxicity
D) Active transport
Rationale: The critical concentration is the concentration of a drug at the receptor site that
must be achieved to produce a therapeutic effect. This concept underlies the relationship
between drug dose, plasma concentration, and clinical response .
QUESTION 5
A nurse is caring for a patient who has been receiving a drug by the intramuscular route
but will receive the drug orally after discharge. How does the nurse explain the
increased dosage prescribed for the oral dose?
A) Passive diffusion
B) Active transport
C) Glomerular filtration
D) First-pass effect
Rationale: The first-pass effect refers to the metabolism of a drug in the liver before it
reaches systemic circulation. Orally administered drugs are absorbed from the GI tract and
transported to the liver via the portal vein, where they may be extensively metabolized.
This reduces bioavailability, often requiring higher oral doses compared to IV or IM
administration .
QUESTION 6
A nurse is working as a member of a research team involved in exploring the unique
response to drugs each individual displays based on genetic make-up. What is this area
of study called?
A) Pharmacotherapeutics
B) Pharmacodynamics
, C) Pharmacoeconomics
D) Pharmacogenomics
Rationale: Pharmacogenomics is the study of how genetic variations influence drug
response. It combines pharmacology and genomics to understand how genetic factors
affect drug metabolism, efficacy, and toxicity. This field enables personalized medicine by
identifying patients who will benefit from specific drugs or require dose adjustments .
QUESTION 7
The nurse is assessing a newly admitted older patient who has recently lost 15 pounds.
The nurse notes that the patient is taking warfarin (Coumadin). Which laboratory tests
will the nurse discuss with this patient's provider?
A) Blood glucose and C-reactive protein
B) Complete blood count and hepatic function tests
C) Renal function tests and serum electrolytes
D) Serum albumin and coagulation studies
Rationale: Warfarin is highly protein-bound (99%) to albumin. In patients with low serum
albumin (e.g., from malnutrition, weight loss, liver disease), the free (unbound) warfarin
concentration increases, leading to enhanced anticoagulant effect and bleeding risk.
Coagulation studies (INR) must be monitored closely. This patient's weight loss warrants
evaluation of nutritional status and albumin levels .
QUESTION 8
A nurse is preparing to care for a patient who is receiving digoxin. When screening for
potential adverse effects from this drug, the nurse will review which of this patient's
laboratory results?
A) Albumin
B) Blood urea nitrogen (BUN) and creatinine
C) Hepatic enzymes
D) Serum electrolytes
FOR ADVANCED PRACTICE NURSES AND PHYSICIAN
ASSISTANTS 3RD EDITION ROSENTHAL |2026 UPDATE
SECTION 1: BASIC PRINCIPLES OF PHARMACOLOGY
(Questions 1-50)
QUESTION 1
A nurse administers the same medication in the same preparation in the same dose to
several patients and notes that some patients have a better response to the drug than
others. What is the most likely explanation for this phenomenon?
A) Altered bioavailability of the drug
B) Patient compliance with the therapeutic regimen
C) Pharmacogenomic differences among individuals
D) Placebo effects enhancing expectations of drug efficacy
Rationale: Pharmacogenomics is the study of how genetic variations affect individual
responses to drugs. Genetic polymorphisms can affect drug-metabolizing enzymes (e.g.,
CYP450), drug transporters, and receptor targets, leading to significant interindividual
differences in drug efficacy and toxicity .
,QUESTION 2
A patient asks a nurse why a friend who is taking the same drug responds differently to
that drug. The nurse knows that the most common variation in drug response is due to
differences in each patient's:
A) Drug receptor sites
B) Hypersensitivity potential
C) Metabolism of drugs
D) Psychosocial response
Rationale: Genetic variations in drug-metabolizing enzymes (e.g., CYP2D6, CYP2C9,
CYP3A4) are the most common cause of interindividual variation in drug response. These
variations affect the rate at which drugs are metabolized and eliminated, leading to
differences in drug levels and clinical effects .
QUESTION 3
The U.S. Food and Drug Administration (FDA) recommends genetic testing of patients
receiving certain medications. Genetic testing helps prescribers:
A) Better establish a drug's therapeutic index
B) Determine whether a patient is a rapid or slow metabolizer of the drug
C) Identify racial characteristics that affect psychosocial variation in drug response
D) Produce a drug that is tailored to an individual patient's genetic makeup
Rationale: Genetic testing identifies polymorphisms in drug-metabolizing enzymes (e.g.,
CYP2C9, CYP2D6, TPMT) that predict whether a patient is a poor, intermediate, or
extensive metabolizer. This information guides dosing decisions to optimize efficacy and
minimize toxicity .
QUESTION 4
What term does the nurse use to describe the drug level required to have a therapeutic
effect?
,A) Critical concentration
B) Dynamic equilibrium
C) Selective toxicity
D) Active transport
Rationale: The critical concentration is the concentration of a drug at the receptor site that
must be achieved to produce a therapeutic effect. This concept underlies the relationship
between drug dose, plasma concentration, and clinical response .
QUESTION 5
A nurse is caring for a patient who has been receiving a drug by the intramuscular route
but will receive the drug orally after discharge. How does the nurse explain the
increased dosage prescribed for the oral dose?
A) Passive diffusion
B) Active transport
C) Glomerular filtration
D) First-pass effect
Rationale: The first-pass effect refers to the metabolism of a drug in the liver before it
reaches systemic circulation. Orally administered drugs are absorbed from the GI tract and
transported to the liver via the portal vein, where they may be extensively metabolized.
This reduces bioavailability, often requiring higher oral doses compared to IV or IM
administration .
QUESTION 6
A nurse is working as a member of a research team involved in exploring the unique
response to drugs each individual displays based on genetic make-up. What is this area
of study called?
A) Pharmacotherapeutics
B) Pharmacodynamics
, C) Pharmacoeconomics
D) Pharmacogenomics
Rationale: Pharmacogenomics is the study of how genetic variations influence drug
response. It combines pharmacology and genomics to understand how genetic factors
affect drug metabolism, efficacy, and toxicity. This field enables personalized medicine by
identifying patients who will benefit from specific drugs or require dose adjustments .
QUESTION 7
The nurse is assessing a newly admitted older patient who has recently lost 15 pounds.
The nurse notes that the patient is taking warfarin (Coumadin). Which laboratory tests
will the nurse discuss with this patient's provider?
A) Blood glucose and C-reactive protein
B) Complete blood count and hepatic function tests
C) Renal function tests and serum electrolytes
D) Serum albumin and coagulation studies
Rationale: Warfarin is highly protein-bound (99%) to albumin. In patients with low serum
albumin (e.g., from malnutrition, weight loss, liver disease), the free (unbound) warfarin
concentration increases, leading to enhanced anticoagulant effect and bleeding risk.
Coagulation studies (INR) must be monitored closely. This patient's weight loss warrants
evaluation of nutritional status and albumin levels .
QUESTION 8
A nurse is preparing to care for a patient who is receiving digoxin. When screening for
potential adverse effects from this drug, the nurse will review which of this patient's
laboratory results?
A) Albumin
B) Blood urea nitrogen (BUN) and creatinine
C) Hepatic enzymes
D) Serum electrolytes
